Elizabeth Clutterbuck
A5032068223- Bacterial Infections and Vaccines
- SARS-CoV-2 and COVID-19 Research
- Pneumonia and Respiratory Infections
- COVID-19 Clinical Research Studies
- Influenza Virus Research Studies
- Respiratory viral infections research
- Immunotherapy and Immune Responses
- SARS-CoV-2 detection and testing
- Vaccine Coverage and Hesitancy
- Viral Infections and Outbreaks Research
- Hepatitis B Virus Studies
- Immunodeficiency and Autoimmune Disorders
- vaccines and immunoinformatics approaches
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Immune Response and Inflammation
- Congenital Diaphragmatic Hernia Studies
- T-cell and B-cell Immunology
- Neonatal Respiratory Health Research
- Animal Virus Infections Studies
- Virus-based gene therapy research
- Viral Infections and Vectors
- Immune responses and vaccinations
- Diabetes and associated disorders
- Horticultural and Viticultural Research
University of Oxford
2016-2025
Oxford BioMedica (United Kingdom)
2014-2025
Churchill Hospital
2017-2022
Institut de Recherche Vaccinale
2021
National Institute for Health Research
2012-2020
National Health Service
2020
Oxford Biomedical Research
2013-2014
Science Oxford
2014
St George's, University of London
2014
Babraham Institute
2014
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity a viral vectored vaccine that expresses spike protein SARS-CoV-2.
Older adults (aged ≥70 years) are at increased risk of severe disease and death if they develop COVID-19 therefore a priority for immunisation should an efficacious vaccine be developed. Immunogenicity vaccines is often worse in older as result immunosenescence. We have reported the immunogenicity novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19 (AZD1222), young adults, now describe safety this wider range participants, including aged 70 years older.In report phase 2 component...
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given an interval 4-12 weeks. planned roll-out in will involve vaccinating people high-risk categories their first dose immediately, delivering second 12 weeks later. Here, we provide both further prespecified pooled analysis trials exploratory analyses impact on immunogenicity efficacy extending...
Abstract The global supply of COVID-19 vaccines remains limited. An understanding the immune response that is predictive protection could facilitate rapid licensure new vaccines. Data from a randomized efficacy trial ChAdOx1 nCoV-19 (AZD1222) vaccine in United Kingdom was analyzed to determine antibody levels associated with against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after second dose were measured infected noninfected recipients. Higher all markers correlated reduced...
Highlights•Reduced B.1.351 neutralization by mAbs and sera induced early SARS-CoV-2 isolates•B.1.351 titer reduced 8- to 9-fold for Pfizer AstraZeneca vaccinees•E484K, K417N, N501Y cause widespread escape from mAbs•NTD deletion in abrogates a potent neutralizing human mAbSummaryThe race produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began when the first sequence was published, this forms basis currently deployed globally. Independent lineages of have...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 contributed to the current wave of infection ravaging Indian subcontinent and been designated a concern in United Kingdom. Here we study ability monoclonal antibodies convalescent vaccine sera neutralize B.1.617.1 B.1.617.2, complement this structural...
<h2>Summary</h2><h3>Background</h3> A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause COVID-19 disease in UK from November, 2020. We report a post-hoc analysis efficacy adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. <h3>Methods</h3> Volunteers (aged ≥18 years) who were enrolled phase 2/3 vaccine studies UK, and randomly assigned (1:1) to receive or meningococcal conjugate control (MenACWY) provided upper airway swabs on weekly basis also if they...
Highlights•Despite similar RBD mutations, P.1 is easier to neutralize than B.1.351•P.1, B.1.351, and B.1.1.7 partially or fully escape most VH3-53 antibodies•mAb 222 (VH3-53) retains neutralization against all three variants•Neutralization restored in chimeric antibodies with mAb LCSummaryTerminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses virus spike derived from early isolates. However, new strains have emerged...
SARS-CoV-2 has caused over 2 million deaths in little a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of pandemic and error-prone replication is leading appearance mutant viruses potentially escape from antibody responses. Variant B.1.1.7, now dominant UK, with increased transmission, harbors 9 amino acid changes spike, including N501Y ACE2 interacting surface. We examine ability B.1.1.7 evade elicited by natural infection or...
<h2>Summary</h2><h3>Background</h3> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic in 2020. Testing is crucial for mitigating public health and economic effects. Serology considered key to population-level surveillance potentially individual-level risk assessment. However, immunoassay performance not been compared on large, identical sample sets. We aimed investigate the of four high-throughput commercial SARS-CoV-2 antibody immunoassays novel...
<h3>Importance</h3> Developing effective vaccines against Ebola virus is a global priority. <h3>Objective</h3> To evaluate an adenovirus type 26 vector vaccine encoding glycoprotein (Ad26.ZEBOV) and modified vaccinia Ankara vaccine, glycoproteins from virus, Sudan Marburg Tai Forest nucleoprotein (MVA-BN-Filo). <h3>Design, Setting, Participants</h3> Single-center, randomized, placebo-controlled, observer-blind, phase 1 trial performed in Oxford, United Kingdom, enrolling healthy 18- to...
Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying severity in an integrated comparison influenza sepsis versus healthy volunteers. identify signatures correlates host response. Hallmarks disease involved cells, their inflammatory mediators networks, including progenitor cells myeloid lymphocyte subsets, features the repertoire,...
Background. A 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP), routinely administered at the age of 65, has limited effectiveness, and revaccination induces attenuated antibody responses. It is not known whether polysaccharide-protein conjugated vaccines (PCV), although highly effective in infants, offer any immunological advantages over 23vP adults.
SummaryBackgroundCOVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between first and second dose becomes longer. Conversely, with no constraints considering administering a third dose. We assessed persistence of immunogenicity after single ChAdOx1 nCoV-19 (AZD1222), an extended (44–45 weeks) dose, response to booster given 28–38 weeks dose.MethodsIn this substudy, volunteers aged 18–55 years who were enrolled phase 1/2...
<ns3:p><ns3:bold>Background:</ns3:bold> The COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out evaluate the performance ELISA lateral flow immunoassay (LFIA) devices.</ns3:p><ns3:p> <ns3:bold>Methods:</ns3:bold> tested plasma COVID (severe acute respiratory...
ABSTRACT Background The COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out evaluate the performance ELISA lateral flow immunoassay (LFIA) devices. Methods tested plasma COVID (SARS-CoV-2) IgM IgG antibodies by using nine different LFIA used a panel samples who...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity varies between individuals, and immune responses correlate with efficacy. Using data from 1,076 participants enrolled in ChAdOx1 nCov-19 efficacy trials the United Kingdom, we found that inter-individual variation normalized antibody against SARS-CoV-2 spike its receptor-binding domain (RBD) at 28 days after first vaccination shows genome-wide significant association major histocompatibility complex...
Significance Vaccines are one of the most cost-effective public health tools in history and offer a means to probe human immune system. Recent advances have applied systems biology study responses vaccination humans. Here we describe application this “systems vaccinology” approach studying immunity 14- 24-mo-old children with inactivated influenza vaccine, administered or without MF59 adjuvant. These results reveal important new insights about dynamics innate adaptive population, identify...